Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer

16 de noviembre de 2026 actualizado por: Lee, Soo Hyeon, Korea University Anam Hospital

A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy

This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.

Descripción general del estudio

Descripción detallada

This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

39

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).

  2. EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.

  3. Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).

  4. Age ≥ 19 years.

  5. ECOG performance status 0-2.

  6. Adequate bone marrow and organ function:

    • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
    • Hemoglobin (Hgb) ≥ 9.0 g/dL
    • Platelet count ≥ 75 x 10^9/L
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
    • Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
    • AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  7. Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).

  8. Ability to swallow oral medication.

  9. Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.

  10. Agreement to use appropriate contraception methods as outlined in the protocol.

  11. Life expectancy ≥ 3 months.

  12. Signed and dated informed consent prior to any study-related procedures.

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
  3. Known hypersensitivity to the study drug components.
  4. Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
  5. Uncontrolled severe infection.
  6. Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
  7. Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
  8. History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
  9. Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
  10. Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
  11. Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
  12. Thrombotic or thromboembolic events within 6 months.
  13. History or evidence of bleeding disorders.
  14. Therapeutic use of maximum dose anticoagulants.
  15. Unhealed wounds, acute ulcers, or bone fractures.
  16. Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
  17. Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
  18. History or pathological findings of major GI surgery that may impair oral absorption.
  19. Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
  20. Conditions or diseases deemed by the investigator to contraindicate study participation.
  21. Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Bevacizumab plus Erlotinib

Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg.

Administered at 7.5 mg/kg intravenously every 3 weeks.

Otros nombres:
  • Onbevzi

Administered at 150 mg orally daily.

Otros nombres:
  • Eltinib

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-Free Survival (PFS)
Periodo de tiempo: From the first dose of study treatment until disease progression or death, assessed up to 12 months

PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause.

From the first dose of study treatment until disease progression or death, assessed up to 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate (ORR)
Periodo de tiempo: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1.

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Overall Survival (OS)
Periodo de tiempo: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up

OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date

From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
Disease Control Rate (DCR)
Periodo de tiempo: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Duration of Response (DOR)
Periodo de tiempo: From initial response until documented disease progression, assessed up to approximately 12 months

Calculated from the time initial response (CR or PR) is documented until the date of progressive disease

From initial response until documented disease progression, assessed up to approximately 12 months
Time to Response (TTR)
Periodo de tiempo: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months

Calculated from the first dose of study treatment to the date of initial response (CR or PR)

From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
Safety and Tolerability
Periodo de tiempo: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months

Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0

From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
Quality of Life (QoL) EORTC QLQ-C30
Periodo de tiempo: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
Quality of Life (QoL) CR26
Periodo de tiempo: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

4 de enero de 2027

Finalización primaria (Estimado)

31 de enero de 2028

Finalización del estudio (Estimado)

31 de enero de 2030

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.

Marco de tiempo para compartir IPD

Beginning 3 months and ending 5 years following article publication.

Criterios de acceso compartido de IPD

De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir